MTOR and cervical cancer: Our results also suggested PKM2 enhanced sensitivity to cisplatin through interaction with the mTOR signaling pathway in cervical cancer, indicating that PKM2 may be a promising target for therapeutic approaches in cervical cancer, as well as other cancers.